Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 4/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001676 | 1.00 | BTK (0.43) | BTKHTR2ADYRK1AGSK3BNFATC1 | |
| SCHEMBL28329840 | 0.85 | HTR2A (0.45) | BTKHTR2ADYRK1AGSK3BNFATC1 | |
| SCHEMBL3065669 | 0.82 | BTK (0.44) | BTKHTR2ADYRK1AGSK3BCDK2 | |
| SCHEMBL31001707 | 0.81 | GABRP (0.56) | BTKGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12326386 | 0.81 | GABRP (0.56) | BTKGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16610310 | 0.81 | BTK (0.40) | BTKGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL19972495 | 0.79 | DGAT2 (0.50) | HTR2ADYRK1AGSK3BNFATC1GABRP | |
| SCHEMBL30861910 | 0.79 | DGAT2 (0.50) | HTR2ADYRK1AGSK3BNFATC1GABRP | |
| SCHEMBL18441278 | 0.79 | SLC6A4 (0.51) | HTR2A | |
| SCHEMBL17495416 | 0.77 | SLC6A4 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3512850-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | BTK 2479/4885HTR2A 4696/4885DYRK1A 2586/4885 |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | BTK 2479/4885HTR2A 4696/4885DYRK1A 2586/4885 |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | BTK 2479/4885HTR2A 4696/4885DYRK1A 2586/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | BTK 2479/4885HTR2A 4696/4885DYRK1A 2586/4885 |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | BTK 2479/4885HTR2A 4696/4885DYRK1A 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.